

# COURSE FACULTY, IAS–USA STAFF, SCIENTIFIC LEADERSHIP BOARD, AND GOVERNANCE BOARD

## FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, Scientific Leadership Board, Governance Board, and program staff) to disclose any financial relationships that have had with ineligible companies (previously defined as “commercial interests”) within the previous 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered and have been mitigated. Individuals who refuse to disclose financial relationships may not participate in an IAS–USA CME activity. The **ACCME defines ineligible companies** as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” Below are the financial interests that faculty members of this course have had within the past 24 months. View the [Faculty Financial Disclosure Policy](#).

ATLANTA, GEORGIA – APRIL 8, 2022

Course Chairs	
<b>Jeffrey Lennox MD</b> Professor of Medicine Emory University Center for AIDS Research Atlanta, Georgia	<i>Dr Lennox has received payment for clinical trials from ViiV Healthcare. (Updated 03/31/22)</i>
<b>Michael S. Saag, MD</b> Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 3/30/22)</i>
Speakers	
<b>Grant Ellsworth, MD, MS</b> Assistant Professor of Medicine Weill Cornell Medicine New York, New York	<i>Dr Ellsworth has no relevant financial affiliations to disclose. (Updated 04/01/22)</i>
<b>Rajesh T. Gandhi, MD</b> Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts	<i>Dr Gandhi has no relevant financial relationships with ineligible companies to declare. (Updated 03/22/22)</i>
<b>Jeffrey Lennox MD</b>	<i>Dr Lennox has received payment for clinical trials from ViiV Healthcare. (Updated 03/31/22)</i>
<b>Michael S. Saag, MD</b>	<i>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 3/30/22)</i>
<b>Dawn K. Smith, MD, MS, MPH</b> Division of HIV Prevention, NCHHSTP Centers for Disease Control and Prevention Atlanta, Georgia	<i>Dr Smith has no relevant financial affiliations to disclose. (Updated 04/01/22)</i>
<b>Melanie Thompson, MD</b> Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia	<i>Dr Thompson's institution has received research grants from Gilead Sciences, Inc, Merck Sharp Dohme, and ViiV Healthcare. She has served on advisory and data safety monitoring boards for Excision Biotherapeutics. (Updated 03/22/22)</i>
Non-Conflicted Planner(s) and Reviewer(s)	
<b>Donna M. Jacobsen</b> Executive Director	<i>Donna M. Jacobsen has no relevant financial relationships with ineligible companies to disclose. (Updated 04/05/22)</i>
<b>Grant Ellsworth, MD, MS</b>	<i>Dr Ellsworth has no relevant financial affiliations to disclose. (Updated 04/01/22)</i>
<b>Rajesh T. Gandhi, MD</b>	<i>Dr Gandhi has no relevant financial relationships with ineligible companies to declare. (Updated 03/22/22)</i>
<b>Dawn K. Smith, MD, MS, MPH</b>	<i>Dr Smith has no relevant financial affiliations to disclose. (Updated 04/01/22)</i>
IAS–USA Board of Directors	
The nonstaff members of the <a href="#">IAS–USA Scientific Advisory Board</a> and <a href="#">Governance Board</a> are not compensated for their roles in governing and overseeing the IAS–USA and content development. Please see the About page on the IAS–USA website for information about board members and a link to up-to-date financial disclosure information.	